BioNeutral Announces Results of "APIC" Conference and Its Launch of Ygiene 206 Sterilant
NEWARK, N.J., July 6, 2011 /PRNewswire/ -- BioNeutral Group, Inc. (OTCBB: BONU) today announced the results of its attendance at the international conference & exhibit for the Association for Professionals in Infection Control (APIC). The conference took place from June 27th through the 29th at the convention center in Baltimore, Maryland. Over 2,200 infection control professionals attended it, from as far away as the United Arab Emirates, representing nearly 1,900 health care institutions along with 207 exhibitors.
It was the first time the company had a formal opportunity to present its Ygiene technology to hundreds of health care institutions and allow highly specialized conference participants to view our products. "I'm pleased to report that our Ygiene 206 Sterilant formulation was very unique to the APIC exhibit hall and was received extremely well by those professionals I presented it to," stated Dr Andy Kielbania , Chief Scientific Officer of BioNeutral. He went on to say, "I did not see any other product at this show new or old, with the overall superior performance characteristics which matched Ygiene 206 Sterilant."
"The company's expectations were quite modest as first time APIC exhibitors and having a small presentation booth. Nevertheless, in 3 days with a total of 10.5 hours of open exhibit time, 257 infection control professionals visited our booth and asked to be in our database for follow up, with 64 of them requesting an initial trial at their facility. This is six times the expected result given the floor space allocated to us, according to those who run the conference for APIC." It was very busy, averaging just under 25 attendees per hour. Overall, I would categorize our launch event as extremely encouraging," stated Stephen J. Browand , Chairman and CEO of BioNeutral Group, Inc.
The company also premiered its all new more informative website now showcased at www.bioneutral.com, that was timed to launch with the APIC conference opening. The entire content was designed to bring the various multifaceted technologies together under a new unified corporate identity.
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, NJ, BioNeutral Group, Inc., is a specialty technology-based life science company which has developed a technology platform that neutralizes harmful environmental contaminants, toxins, and dangerous micro-organisms including bacteria, viruses, mold, fungi, and spores. BioNeutral's products, Ygiene® and Ogiene®, kill microorganisms and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water, and airborne applications. Its antimicrobial line of products under the Ygiene® brand have been approved by the EPA for sale in the United States, have previously been approved for sale in Germany, and are also permitted for sale in the UK, France, and Sweden. AutoNeutral is a registered trademark of BioNeutral Group, Inc. For more information on BioNeutral, including a listing of the Company's products, leadership and background, please visit www.bioneutral.com.
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Group/149109938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene® 206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are now available for sale in the United States
SOURCE BioNeutral Group, Inc.
More by this Source
BioNeutral Gains Initial Market Acceptance
Feb 25, 2013, 09:00 ET
BioNeutral appoints Chairman of its Audit and Executive Compensation Committees
Dec 17, 2012, 16:12 ET
BioNeutral Enters Into Equity Purchase Agreement With Southridge Partners II
Dec 13, 2012, 15:48 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.